1. Executive Summary: The Headline
- Mixed bag with a clear operational beat masked by a one-off. Revenue delivered strong double-digit growth (26th consecutive quarter of sequential expansion), while adjusted/operating PAT rose 5% YoY. Reported PAT fell ~25% YoY due to exceptional Nagarro acquisition costs.
- Overarching narrative: Sustained high-growth execution continues, with solid deal momentum and progress on the Nagarro transaction (now ~94% of share capital secured). Margins saw modest pressure, but the underlying operating performance and growth trajectory remain intact. The exceptional item is the primary distorting factor.
2. Actuals vs. Market Estimates (The Core Analysis)
The exceptional item (Nagarro-related costs) is the key one-off that compresses reported PAT and EPS (₹22.40). On an adjusted basis, the quarter is a clean operational beat on growth and profitability. Margin compression of ~80–130 bps YoY is the main soft spot.
3. Brokerage Stance & Target Revisions
Pre-result stance was constructive to bullish. Motilal Oswal reiterated Buy with a target of ₹6,400 (35x FY28E EPS). HDFC Securities had ADD at ₹6,070. Kotak Institutional Equities had recently double-upgraded to Buy with a raised target of ₹6,250, citing solid execution, organic growth trajectory, and Nagarro accretion potential (combined EPS CAGR seen rising toward ~27%).
No widespread post-result target revisions are available yet (results released after Thursday close). Primary thesis remains high-teens organic growth sustainability plus Nagarro as a second growth leg. Main concern is near-term margin trajectory and integration costs.
4. Management Guidance & Commentary Analysis
Tone is confident and growth-oriented. CEO Sandeep Kalra highlighted the 26th consecutive quarter of growth, $487.6M revenue (+7.8% QoQ / +20% YoY), and 15% EBIT margin. Management emphasized substantial progress on the Nagarro acquisition (securing ~94% of share capital excluding treasury shares) and shareholder approval for an equity raise of up to $450M (with combined equity + borrowings capped at $1.25B) to support the deal.
No major downward revision to growth ambitions is flagged. The company continues to track toward its multi-year revenue targets (with Nagarro expected to contribute from H2). Commentary on AI capabilities, client wins across verticals (Software/Hi-Tech, BFSI, Healthcare), and deal momentum is positive. This aligns with or exceeds street expectations for continued high-teens organic growth while the inorganic overlay is underway.
5. Probable Market Reaction & Trading Setup
Immediate sentiment: Range-bound to mildly positive open on Friday (16 October), with potential for early volatility. Stock closed Thursday at ~₹5,840 (-1%). Base case is a modest gap (flat to +1–2%) that could see two-way trade, as the market digests the one-off versus the underlying growth beat. Support near ₹5,700–5,750; resistance around ₹5,950–6,100.
The “why”: Strong revenue growth (+20% YoY USD, 26th straight quarter) and adjusted PAT (+5% YoY) are positives, but the 25%+ drop in reported PAT from Nagarro costs and modest margin compression (EBIT to 15%) will temper enthusiasm. Investors will focus on whether the exceptional item is truly one-off and how Nagarro integration/synergies are progressing. Deal wins (TCV $633.5M) provide support.
Key catalyst for traders: Clarity on the Nagarro exceptional cost (one-time nature) and any incremental commentary on margin trajectory or synergy timelines. Confirmation that organic growth remains on track and the acquisition is progressing cleanly would support buying or short-covering; prolonged margin pressure or higher integration costs would invite selling.
This is a reaction framework based on the reported numbers and available context, not a recommendation.